Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

AbbVie invests $380m in North Chicago for API manufacturing, creating 300 jobs, boosting US R&D, and expanding domestic ...

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

The thick client is making a comeback. Here’s how next-generation local databases like PGlite and RxDB are bringing ...

Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient ...

The Chicago-based biopharmaceutical company AbbVie made a significant move on Feb. 23, as part of its broader commitment to ...

AbbVie is investing $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its headquarters campus in North Chicago. Construction is set to begin in spring 2026, ...

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A. Goldsmith reiterated that the company ...

AbbVie will build two new active pharmaceutical ingredient manufacturing facilities at its North Chicago headquarters over the next three years, investing $380 million and creating 300 new full-time ...

Just like algae blooms in the ocean and pollen in the spring, there’s been an explosion in the past year or two of new software, related tools and lingo from the IT and mainstream/consumer side. Some ...

Pharmaceutical giant AbbVie is making a substantial strategic pivot, channeling significant investment into its U.S. operations to secure its future in high-growth markets. The company is allocating ...